Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
Sting
CXCR3
DOI:
10.1158/2326-6066.c.6550907.v1
Publication Date:
2023-04-04T19:34:53Z
AUTHORS (49)
ABSTRACT
<div>Abstract<p>Activation of the stimulator interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding mechanism action in human tumors is key developing therapeutic combinations that activate effective innate immunity. Here, we report malignant pleural mesothelioma cells robustly express and are responsive agonist treatment <i>ex vivo</i>. Using dynamic single-cell RNA sequencing explants treated with a agonist, observed CXCR3 chemokine activation primarily tumor cancer-associated fibroblasts, as well T-cell cytotoxicity. In contrast, primary natural killer (NK) resisted agonist–induced enhanced migration killing NK mesothelin-targeted chimeric antigen receptor (CAR)-NK cells, improving activity patient-derived organotypic spheroids. These studies reveal fundamental importance using samples assess cellular immune therapies. By functionally profiling elevated expression uncovered distinct consequences humans support testing combining CAR-NK cell therapies.</p></div>
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (1)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....